For those proponents of psychedelic-assisted therapy concerned that demand for therapists will outstrip supply in the coming years, you may be reassured by today’s conversation with Dr. Ingmar Gorman and Dr. Elizabeth Nielson, psychologists who have been involved in FDA-approved clinical trials of MDMA and psilocybin, and the co-founders of a company called Fluence Training which is working to scale education for this purpose. As they explain to host Shiv Gaglani, they see their task, broadly speaking, as serving three categories of people: those with general interest in the field; all types of clinicians who want to be able to have informed conversations with patients wishing to discuss their current and/or future use; and those who want to become therapists in this modality. Fluence is especially well-positioned for that last group because of Gorman’s and Nielson’s involvement in designing therapy protocols in clinical trials, but also because of their work developing therapy manuals for drug companies. “If and when their drugs go to market, we’ll be able to train clinicians in the community who will be working with those compounds,” says Gorman. One bottom line message in this richly-informed discussion is that the field needs all comers and they hope people aren’t dissuaded by misconceptions about what’s required. “We hear all the time, 'I want to be involved, but I’d have to go back to school and get all these years of clinical experience' when the reality is there's just so many ways now to get involved,” says Nielson. This is a great overview of the status of training, the potential pitfalls awaiting the field, the importance of managing patient expectations, and much more.Mentioned in this episode: https://www.fluencetraining.com/